Appointment of Director
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 11.5 pts less than Nifty Microcap 250 and 11.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hikal Limited's Board of Directors met on May 27, 2026, and approved multiple items. The Board appointed Mr. Sandip Parikh as an Additional Independent Director for a 5-year term, subject to shareholder approval. The company also released audited FY2026 results showing standalone revenue of ₹17,126 million (down from ₹18,598 million in FY2025) and a net loss of ₹487 million after exceptional items. Key exceptional items included a ₹471 million impairment charge for plant repurposing and ₹380 million from new labour code implementation. The Board recommended a final dividend of ₹0.40 per share (20%), bringing total FY2026 dividend to ₹0.60 per share (30%), down from ₹1.40 per share (70%) in the previous year. The Pharma segment was impacted by a USFDA warning letter issued in August 2025 for the Jigani facility.
The appointment of an independent director strengthens board governance. However, the significant decline in revenue, net loss, and reduced dividend payout signal financial stress. Investors should monitor the USFDA warning letter resolution and plant repurposing progress.